Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Depreciation & Amortization (CF) (2018 - 2025)

UroGen Pharma (URGN) has disclosed Depreciation & Amortization (CF) for 8 consecutive years, with $48000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) fell 29.41% year-over-year to $48000.0, compared with a TTM value of $300000.0 through Dec 2025, down 10.71%, and an annual FY2025 reading of $300000.0, down 8.81% over the prior year.
  • Depreciation & Amortization (CF) was $48000.0 for Q4 2025 at UroGen Pharma, down from $100000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $300000.0 in Q3 2022 and bottomed at $48000.0 in Q4 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $156800.0, with a median of $195500.0 recorded in 2021.
  • The sharpest move saw Depreciation & Amortization (CF) skyrocketed 132.93% in 2021, then crashed 66.0% in 2024.
  • Year by year, Depreciation & Amortization (CF) stood at $209000.0 in 2021, then fell by 4.31% to $200000.0 in 2022, then changed by 0.0% to $200000.0 in 2023, then tumbled by 66.0% to $68000.0 in 2024, then fell by 29.41% to $48000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for URGN at $48000.0 in Q4 2025, $100000.0 in Q3 2025, and $52000.0 in Q2 2025.